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This study analysed which route of trastuzumab administration, for the treatment of human epidermal growth 
factor receptor (HER)2-positive breast cancer, was more cost-effective and time saving in relation to active 
healthcare professional time. In clinical practice, trastuzumab subcutaneous treatment resulted in greater cost 
and time savings compared to trastuzumab intravenous treatment. At present, trastuzumab subcutaneous 
treatment should be considered  a clinically equivalent and more cost-effective option to trastuzumab 
intravenous treatment.  
Abstract 
Background Two large acute Irish University teaching hospitals changed the manner in which they treated 
human epidermal growth factor receptor (HER)2-positive breast cancer patients by implementing the 
administration of trastuzumab via the subcutaneous (SC) route into their clinical practice. The study objective is 
to compare the trastuzumab SC and trastuzuamb intravenous (IV) treatment pathways in both hospitals and 
assess which route is more cost-effective and time saving in relation to active healthcare professional (HCP) 
time. 
Materials and Methods A prospective observational study in the form of cost minimisation analysis constituted 
study design. Active HCP time for trastuzumab SC and IV-related tasks were recorded. Staff costs were 
calculated using fully loaded salary costs. Loss of productivity costs for patients were calculated using the 
human capital method. 
Results On average, the total HCP time saved per trastuzumab SC treatment cycle relative to trastuzumab IV 
treatment cycle was 59.21 minutes. Time savings in favour of trastuzumab SC resulted from quicker drug 
reconstitution, no IV catheter installation/removal, and less HCP monitoring. Over a full treatment course of 17 
cycles, average HCP time saved accumulates to 16.78 hours with an estimated direct cost saving of €1,609.99. 
Loss of productivity for patients receiving trastuzumab IV (2.15 days) was greater than that of trastuzumab SC 
(0.60 days) for a full treatment course. 
Conclusion Trastuzumab SC treatment has proven to be a more cost-effective option than trastuzumab IV 
treatment that generated greater HCP time savings in both study sites. Healthcare policymakers should consider 
replacing trastuzumab IV with trastuzumab SC treatment in all eligible patients. 
 


















Breast cancer is the most common cancer in women1, 2. The humanized monoclonal antibody trastuzumab is 
indicated for the treatment of both early and metastatic human epidermal growth factor receptor (HER)2-
positive breast cancer 3. In this group of patients, trastuzumab is administered every three weeks for one year 
(either 17 or 18 treatment cycles depending on the decision of the attending physician) in early breast cancer or, 
in the case of metastatic breast cancer until disease progression, by intravenous (IV) infusion at a dose 
calculated according to the patient’s weight 3. The duration of administration for trastuzumab IV in this 
condition is 90 minutes in the first administration (loading dose) and 30 minutes for consecutive treatment 
administrations (maintenance dose) 3. In addition to the IV formulation, a subcutaneous (SC) formulation exists. 
It has an administration time of less than five minutes and is given by a single-use injection device (SID) or via 
handheld syringe (HHS). The dose is independent of the patient’s weight. The SC formulation has demonstrated 
pharmacokinetics, efficacy, and a safety profile comparable to the IV formulation in patients with early HER2-
positive breast cancer in the enHANced treatment with NeoAdjuvant Herceptin (HannaH) trial 4. Both the safety 
and tolerability of Subcutaneous trastuzumab for the adjuvant treatment of Human epidermal growth factor 
receptor 2-positive early breast cancer (SafeHer) trial and the Preference for subcutaneous or intravenous 
administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer) trial have also 
corroborated these findings 5, 6. 
There are two general approaches to costing healthcare: top-down and bottom-up. A top-down approach 
estimates the cost of an individual service on average, usually using routinely available data e.g. average per 
diem costs. Top-down costing studies tend to be relatively quick and straightforward to conduct, however they 
are also less precise and cannot provide information on individual factors driving the costs 7. Disease-specific 
per diem costs (or daily cost) give the average daily cost for treatments in each disease category but may still be 
quite broad 7. Case-mix groups yield the costs for each category of “case” or hospital patient and take length of 
stay into account. While this approach to costing is more precise than the aforementioned approaches, a bottom-
up approach (micro-costing) generates a more precise estimate but is more onerous to perform. In micro-costing, 
all resources used are identified and then the unit costs of the resources are multiplied by the quantities used 7. 
Studies examining the differences between the cost estimates produced by both top-down and bottom-up 
approaches have concluded that bottom-up approaches are preferable for estimating cost components which 
have a large impact on total costs (e.g. labour, expensive drugs), for services where there is wide variation in 
costs between patients, and for centres which are integrated within a larger hospital compared to independent 
centres 8-11. 
Trastuzumab IV was first launched in Ireland in December 2000 while trastuzumab SC was launched December 
2013 12. The release of trastuzumab SC came at an interesting time when Ireland began to restructure its 
healthcare funding system from one where hospitals are funded based on historical levels of funding adjusted 
for activity and patient mix to a prospective case based payment system (Activity Based Funding) 13. This 
change is currently being implemented for in-patient and day-case activity and will subsequently include 
outpatient services 13. Within the Activity Based Funding system, previously referred to as “Money Follows the 
Patient”, prices will be set initially with reference to average prices, but with an overall aim to implementing 
best practice prices on an incremental basis 13. Therefore, with respect to the contemporaneous reform in the 
Irish healthcare sector, the aim of this study was to estimate the total cost of providing trastuzumab treatments in 
two large acute Irish University teaching hospitals within the south/south west hospital group in the year 2018. 
The perspective of the Irish healthcare service provider was adopted, using a micro-costing approach, and the 
loss of productivity was calculated from a societal perspective. In the Irish context, this is the first economic 








Materials and Methods  
Hospital 1 – Nurse-led clinic  
Hospital 1, a 431 inpatient and 85 day procedure beds teaching hospital, provides general medical, surgical and 
maternity care to approximately 0.5 million patients of southeast Ireland. This hospital is the designated cancer 
centre for southeast Ireland. In 2011, a group of patients in this hospital entered into the SafeHer trial 5. In early 
2014, this hospital began to switch patients from trastuzumab IV to trastuzumab SC and decided to introduce a 
dedicated trastuzumab SC clinic for patients with HER2-positive breast cancer. The approach of moving this 
cohort of patients out of the day oncology ward attempted to improve the patient journey. This hospital took the 
decision to resource the trastuzumab SC clinic with a dedicated clinical nurse specialist (CNS), rather than share 
the resources with the oncology day ward. Clinic times run from 09:30-16:00 where each patient receives an 
allocated 45-minute treatment slot with a 1:1 patient to nurse ratio. 
Hospital 2 – Infusion clinic  
Hospital 2 is a teaching hospital in the south of Ireland that has a designated bed complement of 192 beds and 
caters for up to 38,400 admissions and 72,500 outpatient attendances each year. In late 2015, the pharmacy 
department in this hospital made the decision to switch patients from trastuzumab IV to trastuzumab SC. 
Patients are given either a morning or afternoon appointment in the infusion clinic at this hospital where they are 
attended to on a first come, first served basis by a clinical nurse specialist as per entry into the patient log.  
Cost Minimisation Analysis 
We conducted a prospective observational study in a subgroup of healthcare professionals (HCP) and patients 
with HER2-positive breast cancer that attended both University hospitals between May and June 2018. All data 
were collected by GOB, COM, AK, KC. Both hospitals were each visited on four occasions between April and 
June 2018. Each observation consisted of measuring the time required to perform a specific task related to the 
preparation and administration of trastuzumab. To quantify active HCP time, the time actively invested in 
carrying out the tasks where differences between the routes of administration had been predicted, was observed. 
Figure 1 shows the tasks that both trastuzumab SC and IV treatment pathways have in common where time 
estimates were recorded. Patients receiving adjuvant pertuzumab treatment were excluded. All observations 
were made using a stopwatch. Patient treatment room times (time between entrance and exit from treatment 
room), were inferred from active HCP times. Although not enough sample time estimates were recorded for 
each task to resemble a time and motion study, the estimates gathered were verified by the HCPs involved in the 
study as being a true reflection of average times spent on tasks in routine clinical practice. An average time for 
each task was subsequently calculated and used in the cost analysis. This methodology has been previously seen 
in the literature 14, 15. When a sufficient amount of time estimates were recorded for a particular HCP activity 
associated with trastuzumab preparation, compounding and administration, a student’s t-test was performed for 
the two groups. In all these instances, results were statistically significant (P values < 0.05). Overall, a micro-
costing approach was adopted.  
 
Direct and indirect costs were calculated. Direct costs included HCP costs for the tasks observed (nurses, 
pharmacists, and pharmacy technicians), costs of consumables, and drug costs. Indirect costs included the cost 
of lost productivity. Although both hospitals had been using trastuzumab SC since 2015, contemporaneously 
available healthcare costs, expressed in Euros (€) using 2018 prices (unless otherwise stated), were chosen. 
These updated costs provide a more accurate representation of current spending in the healthcare sector and are 
more useful in the preparation of a budget impact analysis, if required 16.  The perspective of the Irish public 
healthcare provider, the Health Service Executive (HSE), and the societal perspective were adopted. Evidence 
on resource use and patient health outcomes were collected by the research team during the course of the study 
and a retrospective review of patient medical records was conducted. However, this was of no major concern in 
this study given both trastuzumab formulations are clinically equivalent 4. The time horizon for the study was 
less than 2 months thus discounting was not required. Multiple cost components were included in the analysis 
and are described. The mid-point of the HSE healthcare professional pay scale was used and adjusted according 
to guidelines for conducting economic evaluation in Ireland 17, 18. Salary was adjusted for employers’ insurance 






2014 and in hospital 2 in 2015, the 2018 unit cost estimates were deemed appropriate for the analysis as medical 
inflation in Ireland was relatively stable during this period. 
 
The costs of consumables were determined by retrieving invoices issued from the finance department from one 
of the large acute Irish University teaching hospitals in 2018 and calculating unit costs 19 (see Table 2).  Drug 
costs were calculated according to the 2017 reported ex-factory prices (exclusive of value added tax (VAT)) of 
trastuzumab IV 150 mg (€567.69) and trastuzumab SC 600 mg (€1,645.24) 20. The medicinal brand of 
trastuzumab used in both hospitals was Herceptin® and patients were administered the trastuzumab SC 
formulation via a SID 3. All calculations were performed taking an average patient weight of 72.05 kg (average 
weight in Irish women aged 36–64 years 21) treated with trastuzumab for 17 triweekly dosing cycles according 
to the data sheet guidelines where 17 cycles is considered one year of treatment/a full treatment cycle. Patient 
weights were retrieved from CliniChemo pharmacy management software. Patients’ date of births (DOB) and 
sex were retrieved from i.PM (i.Patient Manager). In line with the standard clinical practice, all vials were 
considered used (vial sharing) in patients treated with trastuzumab IV resulting in no drug wastage. The effect of 
possible differences between reported and financed prices was assessed in a sensitivity analysis where discounts 
of 15% in the ex-factory price of the vial of trastuzumab IV and between 15 and 20% in the ex-factory price of 
trastuzumab SC were applied. These rates are believed to mimic national current commercially sensitive 
transactions offered by pharmaceutical manufacturers on biological medicines to Irish hospitals and are 
corroborated by the literature 22, 23. The effect of differences in the weight of patients was analysed in another 
sensitivity analysis in which the costs of treatment in patients weighing between 65 and 75 kg were calculated. 
Vial sharing (no drug wastage) and dose banding tables from the National Cancer Control Programme (NCCP) 
24 were used in association with the recommended triweekly maintenance dose of 6 mg/kg of body weight for 
trastuzumab IV 3. 
Indirect costs were estimated using the human capital method 25 for inferred patient treatment room time. As 
applied in healthcare evaluation, the human capital approach has largely been used to value changes in the 
amount of time individuals are able to allocate to paid work as a result of illness or programmes to alleviate ill-
health 26. According to this approach, the gross wage becomes the unit of value for changes in paid working 
time resulting from healthcare programmes 26. In the context of this study, where the healthcare programme, 
trastuzumab treatment, aims to reduce the patient’s overall mortality risk, the change in productivity cost is 
represented by the present value of the stream of additional days in paid work over the duration of the patient’s 
treatment cycle where each day valued using the gross wage. The average income liable for social insurance in 
Irish women aged 15-84 according to the Irish Department of Social Protection and Revenue Commissioners 
data, adjusted according to current (2018) consumer price index (CPI) inflation, (€27,206.40) 27, 28 was used in 
conjunction with the average recorded unemployment rate for Irish women aged 25–74 as of 2017 (5.4%) 29, 







































Guidelines and Ethical Considerations  
This manuscript followed the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 
guidelines for reporting health economic evaluations 31 (see Electronic Supplementary Material (ESM) Table 
S1). Ethical approval for this study was obtained from the clinical research ethics committee (institutional 
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Medicine administration 
Patient monitoring during treatment 
Ceasing of administration and disposal 
of consumables 







Table 1  Costs of healthcare workers  
Job description Gross annual salary(€)(a) Total cost(€)/year(b) Total cost(€)/min 
Pharmacist  48,071 67,179 0.60 
Pharmacy technician 38,447 53,730 0.48 
Clinical nurse specialist 52,393 73,219 0.65 
Staff nurse 37,508 52,417 0.47 
 
(a) April 2018 Revised HSE Consolidated Pay scales 18. 
 
(b) The mid-point of the HSE pay scale was used and adjusted according to guidelines for conducting 






Costs of consumables 
 
The cost of consumables per treatment cycle was €56.28 for trastuzumab IV and €25.91 for trastuzumab SC, a 
difference of €30.37 excluding the drug costs. For a complete 17-cycle treatment, the cost would be €956.76 for 
trastuzumab IV and €440.47 for trastuzumab SC, resulting in a saving of €516.29 per patient (see Table 2). 
 
Table 2  Costs of consumables in patients treated with trastuzumab IV or trastuzumab SC during a treatment 
cycle  
Different stages of a 
complete treatment cycle 
Cost of preparing 441mg dose 
(3x150mg vials) of trastuzumab IV(€) 
(72.05kg patient(a),(b),(c)) 
Cost of preparing a 600mg dose 
of trastuzumab SC(c) (€) 
Equipment needed Number of items Cost ex-VAT Number of items Cost ex-VAT 
     
Pre-cleaning of LAF     
70/30 IPA wipes  8 7.04 0 0 
     
Preparation 
    
70% alcoholic wipes  20 1.40 14 0.98 
70/30 IPA wipes  8 7.04 8 7.04 
Sharps bin 1 1.35 1 1.35 
Sterile surface mats 2 2.80 2 2.80 
Chemo protect gowns  1 4.67 1 4.67 
Face masks 1 0.68 1 0.68 
Hand gloves 0 0 2 0.04 
Elbow length sterile gloves 1 2.10 0 0 
Head cap 1 0.02 1 0.02 







    
Trastuzumab 150mg vials(b) 3 1669.01 0 0 
Water for injection 10ml 
cartridges 
3 0.27 0 0 
10ml syringe  1 0.12 0 0 
Pink needle 2 0.04 0 0 
Seal for infusion bag  1 0.05 0 0 
Sodium chloride 0.9% 
250ml bag 
1 0.79 0 0 
30ml syringes  1 0.30 0 0 
70/30 Sterile wipes 4 0.28 1 0.07 
Clinichemo labels 2 0.04 2 0.04 
Flag label 0 0 1 0.04 
Green poly bags  1 0.06 1 0.06 
Trastuzumab 600mg vial 0 0 1 1,645.24 
5ml Syringe compatible with 
the closed system device 
0 0 1 1.24 
Vented vial access 
device/adapter 20mm  
0 0 1 1.74 
Cost of running LAF (d) 1 0.05 0 0 
     
Administration 
    
Orange needle  0 0 1 0.02 
Sodium chloride 10ml 0 0 1 0.07 
Sterile swabs 0 0 1 0.06 
Hand gloves 2 0.04 2 0.04 
Fabric plasters  1 0.03 1 0.03 
Alcoholic 2% chlorhexidine 
wipes 
1 0.02 0 0 
Rubber arm band  1 0.45 0 0 
Cannula 1 0.70 0 0 
Rubber bung for cannula  1 0.84 0 0 
Securing tape  1 0.33 0 0 
Opaque infusion giving set  1 5.83 0 0 
Sodium chloride 50ml 2 1.30 0 0 
     
Post-cleaning of LAF 
    
70/30 IPA wipes  8 7.04 0 0 
     





VAT on injectables and all 
















Key: IV – Intravenous, SC – Subcutaneous, VAT – Value Added Tax, LAF – Laminar air flow unit, IPA – 
Isopropyl alcohol 
 
(a) The National Adult Nutrition Survey, which provides average weights, was used in the cost of 
compounding trastuzumab IV (Women: age 36-50 years = 70.5kg, age 51-64 years = 73.6kg, thus  
the mean weight for these prevalent age categories found with HER2-positive breast cancer is 
72.05kg) 21. 
 
(b) Dose banding information on trastuzumab IV provided by the NCCP for a 72.05kg patient required 
441mg of drug (assume vial sharing/no drug wastage) at a maintenance dose of 6mg/kg 24 (initial 
loading dose was excluded). A 450mg dose is prepared in clinical practice to attain 441mg of drug. 
 
(c) Cost of consumables were retrieved from invoices provided by the finance and resource 
department of the hospital 2 19. 
 
(d) Average cost of using a LAF for 900 seconds as per HCP trastuzumab reconstitution time where a 
conversion rate of 1 United States Dollar equals 0.86 Euros as of June 2018 is applied 34. 
Trastuzumab IV was compounded by aseptic technique in the LAF. Trastuzumab SC was 
reconstituted safely on the bench using the closed system for immediate administration. 
 
 
Healthcare professional costs 
 
On average, the cost of HCP time invested in the preparation and administration of trastuzumab was €44.93 per 
cycle of trastuzumab IV and €9.83 per cycle of trastuzumab SC (see Table 3 and Table 4). For a complete 17-
cycle treatment, this would result in a cost of €763.81 for trastuzumab IV and €167.11 for trastuzumab SC, with 
a cost differential of €596.70. Extrapolating these results to a hospital treating 25 patients per year with 
trastuzumab, as per hospitals in this study, the total HCP cost would be €19,095.25 if all patients received 
trastuzumab IV and €4,177.75 if all received trastuzumab SC, with an average saving of €14,917.50 (-78%) 
favourable to trastuzumab SC. 
 







































check by CNS 
342 3.71 331 3.59 
Staff nurse 
double check 
of medicine  
















wipe) by CNS 




45 0.49   
Injection 
administration 
time by CNS 
310 3.36 280 3.03 
Patient after 
care (wipe and 
plaster) by 
CNS 
20 0.22 25 0.27 
Total 965 (16.08 
minutes) 




time of both 
hospitals 
15.44 minutes  Average HCP 
cost of both 
hospitals 
€9.83 
Key: CNS – Clinical nurse specialist, ID – Identification, ECHO – 
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1800  19.50 1800 19.50 
Patient after 
care (wipe and 
plaster) by 
CNS 
182 1.97 167 1.81 
Total 4,582 (76.37 
minutes) 




time of both 
hospitals 
74.65 minutes  Average HCP 
cost of both 
hospitals 
€44.93 
Key: CNS – Clinical nurse specialist, LAF – Laminar air flow unit, ID – 




In the base case (reported ex-factory price inclusive of a VAT rate of 23% 32) and a national average patient 
weight of 72.05 kg 21), the total cost of a 17-cycle treatment would be €34,898.97 for trastuzumab IV and 
€34,401.97 for trastuzumab SC, resulting in a difference of €497.00. In the first sensitivity analysis (discount of 
15% for trastuzumab IV and a range of discounts from 15% to 20% for trastuzumab SC), the cost differences 
between treatments ranged from €1,027.84 to €2,747.93 in favour of trastuzumab SC. In the subsequent 
sensitivity analysis (considering patient weights between 65 and 75 kg and where banded doses for trastuzumab 
IV, recommended by the NCCP, were applied 24), the cost differences between treatments ranged from €-




The average patient treatment room time of both study sites was 841 seconds for trastuzumab SC and 3,052 
seconds for trastuzumab IV (assuming no waiting times for patients). Estimated indirect costs according to lost 
productivity inferred by patient treatment room time for a 17-cycle treatment per patient were €243.74 (loss of 
2.15 working days) for trastuzumab IV and €67.15 (loss of  0.60 working days) for trastuzumab SC. 




Direct costs were €36,619.54 for trastuzumab IV and €35,009.55 for trastuzumab SC, a net difference of 
€1,609.99 in favour of trastuzumab SC. When indirect costs were added, replacement of trastuzumab IV by 
















Table 5  Total costs in patients treated with trastuzumab IV or trastuzumab SC 
 
Costs IV(€) SC(€) Difference(€) 
    
Direct costs 36,619.54 35,009.55 1,609.99 
    
Healthcare professional costs 763.81 167.11 596.70 
Consumable costs 956.76 440.47 516.29 
Drug costs 34,898.97 34,401.97 497.00 
    
Indirect costs 243.74 67.15 176.59 
    
Total costs 36,863.28 35,076.70 1,786.58 
  
Discussion  
This study describes active HCP time invested in the preparation and administration of trastuzumab. A time 
saving of 79% is accrued by the replacement of trastuzumab IV with trastuzumab SC. In fact, the authors 
believe this is the highest recorded active HCP time saving where other studies report time savings of 51% in 
Spain, 48% in Canada and Russia, 36% in France, 31% in Denmark and 15% in Switzerland 35. Greater 
available HCP time could result in improvements in the quality of care, with more time free for monitoring, 
other relevant medical duties or indeed providing patient information or comforting. In addition, by utilising 
trastuzumab SC in the place of trastuzumab IV, a saving of €596.70 per patient in active HCP time for a full 17-
cycle treatment is gained. This result is consistent with those of international studies 36-39. 
The reduction in patient treatment room time resulted in a difference in indirect costs of €176.59 per 17-cycle 
treatment in favour of trastuzumab SC, a conservative estimate that only considered lost productivity between 
entering and leaving the patient treatment room. Moreover, this reduction in patient treatment room time could 
allow the treatment of the same number of patients with fewer resources or more patients with the same 
resources. As well as the economic implications, quality of life may improve with the time savings associated 
with trastuzumab SC. Indeed, a key finding of the PrefHer study was that patients favoured trastuzumab SC as it 
accumulated more time saved for them relative to trastuzumab IV treatment 6. Hence, more than just an estimate 
of costs from the social perspective, according to preferences conveyed, we see that the patient can be the main 
beneficiary. Quality of life is especially important to those patients with metastatic breast cancer as theirs is a 
chronic illness and so minimising the time spent in hospital is an important factor in survivorship. 
Drug cost savings from switching to trastuzumab SC may be underestimated in this study. The National Adult 
Nutrition Survey was used in the cost of compounding trastuzumab IV, (Women: age 36-50 years = 70.5kg, age 
51-64 years = 73.6kg, thus, the mean weight for these prevalent age categories found with HER2-positive breast 
cancer is 72.05kg). This average weight is an underestimate of the true patient weight as Ireland tackles a rising 
obesity problem 40. The mean patient weight for between both centres was 73.44 kg with a range of 43.5kg-
125kg. Therefore, by using the average recommended weight of 72.05kg, the trastuzumab IV formulation may 
appear less costly than it actually is in practice. As per sensitivity analyses, drug costs for trastuzumab IV are 
currently lower than drug costs for trastuzumab SC for patients only for patients weighing ≤ 69kg. For patients 
weighing ≥70 kg, drug costs for trastuzumab IV begin to drastically increase relative to drug costs for 
trastuzumab SC.  
 
In addition, for the recommended weight of 72.05kg, a maintenance trastuzumab IV dose of 6mg/kg 3 would 
require 432.3mg of drug. This is rounded to 441mg according to the national dose banding tables 24 provided by 
the NCCP. This results in 9mg of drug remaining after each trastuzumab 150mg vial reconstitution. Over 17 
triweekly cycles, this equates to 153mg of drug remaining. In this study, we assume vial sharing and no drug 
wastage. However, in clinical practice, it is unlikely this amount of drug would be utilised as 9mg of drug is a 






upon reconstitution. Therefore, it is possible that the cost of 17 triweekly cycles of the trastuzumab IV is 
appearing €712.22 cheaper per patient than it actually is. A loading dose of 8mg/kg is required for patients when 
starting trastuzumab IV therapy or if patients misses their scheduled dose of trastuzumab IV by more than one 
week 3. This presents an additional cost for trastuzumab IV which was omitted in this analysis. There is no 
initial loading dose for starting treatment or missed treatment with trastuzumab SC 41 resulting in this 
formulation being a more cost-effective option under these circumstances. 
 
The main limitation of the study was that not enough time estimates were recorded to conduct a time and motion 
analysis. Although the estimates gathered were verified by the involved HCPs as being a true reflection of 
average times spent on tasks in routine clinical practice, a time and motion study, which gathers data on HCP 
time required to complete the observed tasks, would reduce uncertainty surrounding such inputs. As per other 
time and motion studies investigating this trastuzumab formulation switch, it would have been desirable to 
record hospital time (time between entry and exit from the hospital), and patient travel to the hospital, or the 
time lost by accompanying persons, by means of patient interview when calculating indirect costs 22. These 
measurements would capture a broader societal perspective. Two recent time and motion studies have 
demonstrated that a transition to both trastuzumab and rituximab SC formulations from their respective IV 
formulations resulted in saved patient chair and active HCP times 35, 42. 
This study was carried out in only two centres where differences in clinical practice exist. At times, it was 
difficult to compare clinical practice procedures for the analysis. However, as this study was conducted in 
routine clinical practice settings yielding real world data, as opposed to a study within/alongside a randomised 
controlled trial, the results are more generalizable. This study’s design and setting may also explain why the 
active HCP time savings value of 79% is numerically higher than those corresponding values reported by time 
and motion studies conducted within open-label randomised crossover studies 35. Nonetheless, as trastuzumab 
SC gains traction in the Irish healthcare setting; further research in more hospital sites should be conducted to 
corroborate these study findings.  
At the time of data collection, one of the 48 patients receiving trastuzumab treatment was male. However, as the 
epidemiology of women with HER-2 breast cancer is much greater in females than males 43, indirect costs and 
loss of productivity were calculated using statistics based on data gathered for Irish females. If this method was 
calculated for males, it is likely the indirect costs and loss of productivity would be greater based on data 
gathered for Irish males 27. 
A potential limitation in this study is the issue of “dead time” i.e. the five minute time period required for 
trastuzumab IV to dissolve upon reconstitution 3 and its 30 minute infusion time. While it is potentially possible 
that the HCP could conduct other medical duties during this dead time, such tasks were impossible to cost. The 
issue of dead time and potential medical opportunity cost is a controversial one in the field of costing 44. In 
addition, as best clinical practices are adopted in these two large Irish University teaching hospitals (e.g. vial 
sharing); it was observed that the CNS upheld their duty of care by monitoring patients closely during the 30 
minute trastuzumab IV infusion period for fear of adverse drug reactions which limited their ability to perform 
other activities in parallel. 
For trastuzumab IV, patients should be observed for at least six hours after the start of the first infusion and for 
two hours after the start of the subsequent infusions for symptoms like fever and chills or other infusion-related 
symptoms 3. For trastuzumab SC, patients should be observed for six hours after the first injection and for two 
hours after subsequent injections for signs or symptoms of administration-related reactions 41. Follow-up time 
was excluded from the cost minimisation analysis, as no cost differential existed. In clinical practice, patients 
were strongly advised to remain in clinic for the recommended follow-up time but this was seldom adhered to 
by patients. This variability in follow-up time from patients was not measured which means the loss of 
productivity may be underestimated in this study. Paracetamol treatment (by mouth or by IV infusion) was 
recommended for both trastuzumab IV and SC treatment cycles. Therefore, as no cost differential exists, it too 
was excluded from the cost analysis. As with follow-up time, there was unpredictability in this variable too 






At present, it can be argued that this study is only of interest to hospital budget decision-makers within the 
south/south west hospital group in Ireland. This issue also arose in a similar study where the results of an 
economic evaluation of propofol/fentanyl compared with midazolam/fentanyl on recovery in the intensive care 
unit following cardiac surgery was only of interest to the local hospital 45. However, more Irish hospitals are 
beginning to use trastuzumab SC and following the successful implementation of trastuzumab SC in Europe, 
Oceania and South America 22, 46, 47, it is envisaged this formulation will penetrate the North American oncology 
landscape next. Furthermore, in relation to the current oncology field, biosimilar trastuzumab IV is now 
available 48. It has been approved in Ireland since June 2018, where the biosimilar trastuzumab IV 150mg vial 
Herzuma® yields a drug cost of €401.86 (exclusive of VAT) 49. This is in comparison to the Herceptin® IV 150 
mg vial which yields a drug cost of €567.69 (exclusive of VAT) 20. The individual summary of product 
characteristics for both medicinal products appear almost identical 3, 48 thus it can be assumed that medicine 
reconstitution and administration tasks are equivalent, meaning the only major differential between the two 
products is the drug acquisition cost. It is also worth noting that local commercially sensitive price reductions 
are sometimes offered to payers who switch to biosimilar medicines 50. It will be interesting to see what impact 
biosimilar trastuzumab will have on the Irish and international markets. 
Subcutaneous versions of different oncology therapies have been available for patients for a while now, 
however it is only recently that patient-relevant and hospital benefits are being assessed 35, 51. Although open to 
debate, the literature seems to be favouring subcutaneous oncology treatments over intravenous oncology 
treatments in terms of patient preference, time and cost savings 6, 22, 35, 42, 46, 51, 52. A recent International Society 
for Pharmacoeconomics and Outcomes Research (ISPOR) Special Task Force report identified and defined a 
series of elements that warrant consideration in value assessments of medical technologies 53. In the report, 
Lakdawalla et al. discuss that some medical technologies offer advantages over existing alternatives such as 
simpler dosing schedules, alternate routes of administration, or combination treatments. To the extent that these 
improve patient adherence to treatments and health outcomes, they may impact the estimation of the value of the 
medical technology in the aggregate 54. It is evident from this study that the trastuzumab SC formulation offers 
this advantage over the trastuzumab IV formulation. Trastuzumab SC also reduces the need for cannulation of 
patients whose veins are often compromised due to previous therapies and tests. 
In this study, we attempt to capture the societal perspective by calculating the loss of productivity via the human 
capital method as well as presenting the more common healthcare payer perspective. Sanders et al. 
recommended for the sake of consistency and comparability, analysts should report “reference cases” from two 
perspectives—the healthcare sector perspective and the societal perspective 55. This was also corroborated by an 
ISPOR Special Task Force report 56. In addition, Olsen and Richardson argue that the part of productivity effects 
may be included to the extent that it results in increased resources available for healthcare 57. In fact, if the 
trastuzumab SC formulation was taken out of the secondary care setting and supplied to patients via their local 
pharmacy for self-injection at home, the loss of productivity would virtually be eliminated as patients could 
avoid going to hospital. In conjunction, this would alleviate some of the workload that the exhausted secondary 
care system already encounters. Ireland has devised a ten-year plan for health reform through political 
consensus called Sláintecare which is currently underway 58. Its aim is to establish a universal, single-tier health 
service where patients are treated solely on the basis of health need but it also plans to re-orient the health 
system ‘towards integrated primary and community care that is consistent with the highest quality of patient 
safety in as short a time-frame as possible 59. In line with the overarching aim of Sláintecare, the transplantation 
of trastuzumab SC treatment to the primary care sector would also satisfy patient needs who prefer home and 
community based medical treatments 60. 
Accurate cost data are essential for ensuring breast cancer services are effective, efficient, and equitable and 
costing information should be used to guide policy, planning and implementation in this field. This is 
particularly pertinent in the current situation in Ireland, as healthcare funding is undergoing restructuring 13. As 
demands on the service increase due to greater numbers of patients 61 and more complex care, the cost data 
presented in this analysis will be available for cost-effectiveness evaluations of new drugs, technologies and 






trastuzumab IV to trastuzumab SC in Ireland. The present study has implemented recommendations from the 
CHEERS statement to ensure that this manuscript presents a transparent high quality evaluation.    
 
Conclusion  
In conclusion, the replacement of trastuzumab IV by trastuzumab SC within two large acute Irish teaching 
hospitals has proven to be a more cost-effective approach reducing active HCP time, patient treatment room 
time, and therefore improving patients’ quality of life. With respect to the Irish healthcare landscape, these 
reductions in time result in economic savings, more efficient resource use and improved quality of care. 
Trastuzumab SC reduces the cost of consumables. Dependent on the patient’s weight and the hospital’s policy 
on vial sharing, trastuzumab SC did not always result in drug cost savings. A full treatment cycle of trastuzumab 
SC results in total estimated direct cost savings of €1,609.99. Every year, between 400 and 500 new cases of 
HER2-positive breast cancer present in Ireland 61 where such patients would be potentially eligible for treatment 
with trastuzumab. The widespread use of trastuzumab SC for these patients would not only result in direct cost 
savings but would also lead to a reduction in indirect costs due to a decrease in the loss of productivity. These 
clinical and economic aspects demonstrate that trastuzumab SC results in benefits for patients, HCP, and indeed, 
wider society. 
 
Clinical Practice Points 
• In line with the current evidence, trastuzumab is the standard of care for HER2-positive breast cancer. 
 
• The trastuzuamb SC formulation has demonstrated pharmacokinetics, efficacy, and a safety profile 
comparable to the IV formulation. 
 
• There is an increasing body of literature that favours the use of trastuzumab SC over trastuzumab IV. 
 
 
• In the Irish context, total HCP time saved per trastuzumab SC treatment cycle relative to trastuzumab 
IV treatment cycle was 59.21 minutes. Time savings in favour of trastuzumab SC resulted from quicker 
drug reconstitution, no IV catheter installation and removal, and less HCP monitoring.  
 
• Average HCP time saved summed to 16.78 hours with a total estimated direct cost saving of €1,609.99. 
Loss of productivity for patients receiving trastuzumab IV (2.15 days) was greater than that of 
trastuzumab SC (0.60 days) for a full treatment course. 
 
• Globally, active HCP time savings were similar to those reported in this study. Countries in Europe 
accumulated active HCP time savings as high as 51% whereas Canada cumulated time savings of 36%. 
 
• When available, subcutaneous administration of trastuzumab is preferable in terms of cost 
effectiveness, patient convenience and satisfaction and should be recommended over intravenous 
administration of trastuzumab when possible. 
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